Abstract
To investigate subconjunctival bevacizumab as an adjuvant in first-time glaucoma filtration surgery, we conducted a non-comparative, interventional case series, enrolling consecutive patients with uncontrolled primary glaucomas. All patients underwent trabeculectomy with mitomycin C and received a 1.25 mg subconjunctival bevacizumab injection at completion of the surgery. Main outcome measurements were success rates, bleb morphology [standardized classification based on vascularity (0–1), extension (0–1) and height (0–1); ranging from 0 to 3 (0 = poor; 1 = regular; 2 = good; 3 = excellent)] and post-operative complications. Twenty-five eyes from 25 patients (mean age 64.3 ± 12.8 years) were included. After a mean follow-up of 16.7 ± 6.1 months, mean intraocular pressure (IOP) was significantly reduced from 22.7 ± 10.8 to 12.9 ± 4.3 mmHg at the last follow-up (p < 0.01). Complete success rates at 12 months ranged between 71 and 88 %, while qualified success rates ranged between 84 and 96 %, depending on the criterion adopted (the strictest success criterion was defined as IOP between 6 and 12 mmHg). Blebs were graded as good or excellent in 80 % of the cases. No serious post-operative complication or avascular blebs were observed. These mid-term results suggest subconjunctival bevacizumab as a safe and effective adjuvant in first-time filtration surgery for primary glaucoma patients.
This is a preview of subscription content, log in via an institution to check access.
References
Weinreb RN, Khaw PT (2004) Primary open-angle glaucoma. Lancet 363:1711–1720
Quigley HA (1996) Number of people with glaucoma worldwide. Br J Ophthalmol 80:389–393
Kass MA, Heuer DK, Higginbotham EJ et al (2002) The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 120:701–713
Collaborative Normal-Tension Glaucoma Study Group (1998) The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol 126:498–505
Collaborative Normal-Tension Glaucoma Study Group (1998) Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol 126:487–497
Heijl A, Leske MC, Bengtsson B et al (2002) Reduction of intraocular pressure and glaucoma progression: results from the early manifest glaucoma trial. Arch Ophthalmol 120:1268–1279
Cairns JE (1968) Trabeculectomy. Preliminary report of a new method. Am J Ophthalmol 66:673–679
Suzuki R, Dickens CJ, Iwach AG et al (2002) Long-term follow-up of initially successful trabeculectomy with 5-fluorouracil injections. Ophthalmology 109:1921–1924
The Fluorouracil Filtering Surgery Study Group (1996) Five-year follow-up of the Fluorouracil Filtering Surgery Study. Am J Ophthalmol 121:349–366
How A, Chua JLL, Charlton A et al (2010) Combined treatment with bevacizumab and 5-fluorouracil attenuates the postoperative scarring response after experimental glaucoma filtration. Invest Ophthalmol Vis Sci 51:928–932
Li Z, Van Bergen T, Van de Veire S et al (2009) Inhibition of vascular endothelial growth factor reduces scar formation after glaucoma filtration surgery. Invest Ophthalmol Vis Sci 50:5217–5225
Marey HM, Ellakwa AF (2011) Intravitreal bevacizumab with or without mitomycin C trabeculectomy in the treatment of neovascular glaucoma. Clin Ophthalmol 5:841–845
Takihara Y, Inatami M, Kawaii T et al (2011) Combined intravitreal bevacizumab and trabeculectomy with mitomycin C versus trabeculectomy with mitomycin C alone for neovascular glaucoma. J Glaucoma 20:196–201
Alkawas AA, Shahien EA, Hussein AM (2010) Management of neovascular glaucoma with panretinal photocoagulation, intravitreal bevacizumab, and subsequent trabeculectomy with mitomycin C. J Glaucoma 19:622–626
Chen CH, Lai IC, Wu PC et al (2010) Adjunctive intravitreal bevacizumab-combined trabeculectomy versus trabeculectomy alone in the treatment of neovascular glaucoma. J Ocul Pharmacol Ther 26:111–118
Chen TC, Wilensky JT, Viana MA (1997) Long-term follow-up of initially successful trabeculectomy. Ophthalmology 104:1120–1125
Nouri-Mahdavi K, Brigatti L, Weitzman M et al (1995) Outcomes of trabeculectomy for primary open-angle glaucoma. Ophthalmology 102:1760–1769
Vesti E, Raitta C (1997) A review of the outcome of trabeculectomy in open-angle glaucoma. Ophthalmic Surg Lasers 28:128–132
Jacobi PC, Dietlein TS, Krieglstein GK (1999) Primary trabeculectomy in young adults: long-term clinical results and factors influencing the outcome. Ophthalmic Surg Lasers 30:637–646
Shigeeda T, Tomidokoro A, Chen YN et al (2006) Long-term follow-up of initial trabeculectomy with mitomycin C for primary open-angle glaucoma in Japanese patients. J Glaucoma 15:195–199
Van Bergen T, Vandewalle E, Van de Veire S et al (2011) The role of different VEGF isoforms in scar formation after glaucoma filtration surgery. Exp Eye Res 93:689–699
Mathew R, Barton K (2011) Anti-vascular endothelial growth factor therapy in glaucoma filtration surgery. Am J Ophthalmol 152:10–15
Grewal DS, Jain R, Kumar H et al (2008) Evaluation of subconjunctival bevacizumab as an adjunct to trabeculectomy. Ophthalmology 115:2141–2145
Nilforushan N, Yadgari M, Kish SK (2012) Subconjunctival bevacizumab versus mitomycin C adjunctive to trabeculectomy. Am J Ophthalmol 153:352–357
Acknowledgments
Conflict of interest
The authors have no conflict of interest regarding the present study.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Biteli, L.G., Prata, T.S. Subconjunctival bevacizumab as an adjuvant in first-time filtration surgery for patients with primary glaucomas. Int Ophthalmol 33, 741–746 (2013). https://doi.org/10.1007/s10792-012-9704-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10792-012-9704-4